vs

Side-by-side financial comparison of AMREP CORP. (AXR) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.

AMREP CORP. is the larger business by last-quarter revenue ($14.6M vs $8.6M, roughly 1.7× Sunshine Biopharma Inc.). AMREP CORP. runs the higher net margin — 21.6% vs -25.0%, a 46.6% gap on every dollar of revenue. On growth, AMREP CORP. posted the faster year-over-year revenue change (93.8% vs -10.6%). AMREP CORP. produced more free cash flow last quarter ($5.4M vs $-1.6M). Over the past eight quarters, Sunshine Biopharma Inc.'s revenue compounded faster (6.6% CAGR vs -13.6%).

AMREP Corporation is a real estate and media services company based in Princeton, New Jersey, in the United States. It was founded in 1961 as The American Realty and Petroleum Corporation.

Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.

AXR vs SBFM — Head-to-Head

Bigger by revenue
AXR
AXR
1.7× larger
AXR
$14.6M
$8.6M
SBFM
Growing faster (revenue YoY)
AXR
AXR
+104.4% gap
AXR
93.8%
-10.6%
SBFM
Higher net margin
AXR
AXR
46.6% more per $
AXR
21.6%
-25.0%
SBFM
More free cash flow
AXR
AXR
$7.0M more FCF
AXR
$5.4M
$-1.6M
SBFM
Faster 2-yr revenue CAGR
SBFM
SBFM
Annualised
SBFM
6.6%
-13.6%
AXR

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
AXR
AXR
SBFM
SBFM
Revenue
$14.6M
$8.6M
Net Profit
$3.1M
$-2.1M
Gross Margin
35.3%
Operating Margin
20.6%
-20.9%
Net Margin
21.6%
-25.0%
Revenue YoY
93.8%
-10.6%
Net Profit YoY
338.9%
0.8%
EPS (diluted)
$0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXR
AXR
SBFM
SBFM
Q1 26
$14.6M
Q4 25
$9.4M
$8.6M
Q3 25
$17.9M
$9.4M
Q2 25
$11.2M
$9.4M
Q1 25
$7.5M
$8.9M
Q4 24
$11.9M
$9.6M
Q3 24
$19.1M
$8.4M
Q2 24
$19.5M
$9.3M
Net Profit
AXR
AXR
SBFM
SBFM
Q1 26
$3.1M
Q4 25
$1.2M
$-2.1M
Q3 25
$4.7M
$-883.8K
Q2 25
$3.9M
$-1.8M
Q1 25
$717.0K
$-1.2M
Q4 24
$4.0M
$-2.2M
Q3 24
$4.1M
$-1.2M
Q2 24
$4.1M
$-494.3K
Gross Margin
AXR
AXR
SBFM
SBFM
Q1 26
Q4 25
35.3%
Q3 25
32.6%
Q2 25
36.4%
Q1 25
30.7%
Q4 24
32.2%
Q3 24
34.0%
Q2 24
25.3%
Operating Margin
AXR
AXR
SBFM
SBFM
Q1 26
20.6%
Q4 25
11.9%
-20.9%
Q3 25
34.4%
-11.5%
Q2 25
31.7%
-21.8%
Q1 25
5.7%
-14.6%
Q4 24
26.4%
-21.7%
Q3 24
26.1%
-13.1%
Q2 24
23.9%
-13.6%
Net Margin
AXR
AXR
SBFM
SBFM
Q1 26
21.6%
Q4 25
12.8%
-25.0%
Q3 25
26.3%
-9.4%
Q2 25
34.8%
-18.8%
Q1 25
9.5%
-13.3%
Q4 24
33.9%
-22.5%
Q3 24
21.3%
-14.2%
Q2 24
21.2%
-5.3%
EPS (diluted)
AXR
AXR
SBFM
SBFM
Q1 26
$0.58
Q4 25
$0.22
Q3 25
$0.87
$-0.54
Q2 25
$0.73
$-0.82
Q1 25
$0.13
$-0.44
Q4 24
$0.75
$49.77
Q3 24
$0.76
$-11.61
Q2 24
$0.77
$-43.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXR
AXR
SBFM
SBFM
Cash + ST InvestmentsLiquidity on hand
$50.0M
Total DebtLower is stronger
$21.0K
Stockholders' EquityBook value
$139.4M
$23.0M
Total Assets
$143.9M
$30.1M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXR
AXR
SBFM
SBFM
Q1 26
$50.0M
Q4 25
$44.6M
Q3 25
$48.9M
Q2 25
$39.5M
Q1 25
$36.9M
Q4 24
$40.1M
Q3 24
$40.4M
Q2 24
$29.7M
Total Debt
AXR
AXR
SBFM
SBFM
Q1 26
$21.0K
Q4 25
$23.0K
Q3 25
$25.0K
Q2 25
$26.0K
Q1 25
$29.0K
Q4 24
$32.0K
Q3 24
$34.0K
Q2 24
$35.0K
Stockholders' Equity
AXR
AXR
SBFM
SBFM
Q1 26
$139.4M
Q4 25
$136.0M
$23.0M
Q3 25
$134.7M
$24.2M
Q2 25
$130.0M
$25.7M
Q1 25
$126.0M
$22.7M
Q4 24
$125.1M
$23.5M
Q3 24
$122.2M
$25.0M
Q2 24
$118.0M
$23.5M
Total Assets
AXR
AXR
SBFM
SBFM
Q1 26
$143.9M
Q4 25
$140.1M
$30.1M
Q3 25
$140.7M
$31.5M
Q2 25
$133.8M
$32.0M
Q1 25
$128.9M
$29.2M
Q4 24
$129.1M
$30.6M
Q3 24
$127.0M
$30.1M
Q2 24
$122.8M
$29.3M
Debt / Equity
AXR
AXR
SBFM
SBFM
Q1 26
0.00×
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXR
AXR
SBFM
SBFM
Operating Cash FlowLast quarter
$5.4M
$-1.6M
Free Cash FlowOCF − Capex
$5.4M
$-1.6M
FCF MarginFCF / Revenue
37.0%
-18.9%
Capex IntensityCapex / Revenue
0.1%
0.0%
Cash ConversionOCF / Net Profit
1.72×
TTM Free Cash FlowTrailing 4 quarters
$20.2M
$-5.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXR
AXR
SBFM
SBFM
Q1 26
$5.4M
Q4 25
$-4.3M
$-1.6M
Q3 25
$9.5M
$-727.8K
Q2 25
$10.2M
$-1.3M
Q1 25
$-3.2M
$-1.7M
Q4 24
$-182.0K
$-3.4M
Q3 24
$10.7M
$-1.4M
Q2 24
$10.7M
$-4.6M
Free Cash Flow
AXR
AXR
SBFM
SBFM
Q1 26
$5.4M
Q4 25
$-4.3M
$-1.6M
Q3 25
$9.5M
$-735.8K
Q2 25
$9.7M
$-1.4M
Q1 25
$-3.3M
$-1.7M
Q4 24
$-268.0K
$-3.5M
Q3 24
$10.7M
$-1.9M
Q2 24
$10.3M
$-5.6M
FCF Margin
AXR
AXR
SBFM
SBFM
Q1 26
37.0%
Q4 25
-45.9%
-18.9%
Q3 25
53.2%
-7.8%
Q2 25
86.4%
-15.2%
Q1 25
-43.4%
-19.3%
Q4 24
-2.3%
-36.6%
Q3 24
55.8%
-22.2%
Q2 24
52.5%
-59.7%
Capex Intensity
AXR
AXR
SBFM
SBFM
Q1 26
0.1%
Q4 25
0.6%
0.0%
Q3 25
0.1%
0.1%
Q2 25
5.2%
1.7%
Q1 25
0.3%
0.1%
Q4 24
0.7%
1.1%
Q3 24
0.2%
6.1%
Q2 24
2.3%
10.5%
Cash Conversion
AXR
AXR
SBFM
SBFM
Q1 26
1.72×
Q4 25
-3.54×
Q3 25
2.03×
Q2 25
2.63×
Q1 25
-4.51×
Q4 24
-0.05×
Q3 24
2.63×
Q2 24
2.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons